{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:42:47Z","timestamp":1786372967806,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,2]]},"abstract":"\n Key Points<\/jats:title>\n \n \n \n Among 228 FSGS patients treated with immunosuppression, only 55% achieved remission with relapse rates of 63% and 74% by 2 years.<\/jats:p>\n <\/jats:list-item>\n \n Over a median follow-up of 4 years, 39% of FSGS treated patients progressed to kidney failure, and a total of 27% died.<\/jats:p>\n <\/jats:list-item>\n \n Nonresponders to immunosuppression had a >2-fold risk of kidney failure compared with responders.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n FSGS has a variable response to immunosuppressive (IS) therapy and high relapse rates. Lack of US Food and Drug Administration\u2013approved therapies underscore the need for real-world evidence to better understand treatment patterns and outcomes. This study aimed to evaluate treatment response, relapse patterns, and kidney outcomes among patients with primary FSGS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A retrospective cohort study was performed within 14 medical centers of an integrated health system. Patients (18 years or older) with biopsy-confirmed primary FSGS treated with IS between 2010 and 2021 were included. Treatment response, assessed at up to 8 months, was categorized as complete remission: urine protein-to-creatinine ratio (UPCR) <0.3 g\/g, partial remission: UPCR decline >50% from baseline and between 0.3 and 3.5 g\/g, and no remission. Relapse was defined as loss of remission within 2 years. Outcomes, including ESKD (treatment with dialysis or transplant) and mortality, were analyzed using Fine-Gray subdistribution hazard ratio (sHR) models.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 228 patients treated with IS, 55% achieved remission (12% complete remission, 43% partial remission), with relapse rates of 63% and 75% by 2 years. The median follow-up was 4 years (interquartile range, 2.0\u20137.6), during which 88 (39%) progressed to ESKD. A total of 62 (27%) patients died, with 33 (15%) deaths occurring before reaching ESKD. Nonresponders had a higher risk of ESKD compared with responders (sHR, 2.22; 95% confidence interval [CI], 1.41 to 3.49). Baseline eGFR <30 ml\/min per 1.73 m\n 2<\/jats:sup>\n was strongly associated with risk of ESKD (sHR for eGFR of <30 versus 60+, 4.74; 95% CI, 2.24 to 10.05;\n P<\/jats:italic>\n < 0.001), while baseline proteinuria (UPCR >3.5 g\/g) was NS. Asian\/Pacific Islander patients exhibited the highest ESKD risk among racial\/ethnic groups (sHR, 2.03; 95% CI, 1.07 to 3.84).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Approximately half of FSGS patients achieved remission with IS, but relapse rates were high, and nearly 40% progressed to ESKD. Nonresponders and low baseline eGFR had the highest risk. These findings underscore the need for novel therapies to achieve durable disease control, lower relapse rates, and improve outcomes in FSGS.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.0000000898","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:07:52Z","timestamp":1759853272000},"page":"296-305","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-8243","authenticated-orcid":false,"given":"John J.","family":"Sim","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California"},{"name":"Department Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"},{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes A.","family":"Munis","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Lewing","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-7806","authenticated-orcid":false,"given":"Qiaoling","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1469-6470","authenticated-orcid":false,"given":"Matthew","family":"Hill","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-3183","authenticated-orcid":false,"given":"Min","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Visterra Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ancilla W.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6207-1221","authenticated-orcid":false,"given":"Asher D.","family":"Schachter","sequence":"additional","affiliation":[{"name":"Visterra Inc., Waltham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"6","key":"B1-20260318","doi-asserted-by":"crossref","first-page":"100826","DOI":"10.1016\/j.xkme.2024.100826","article-title":"A review of focal segmental glomerulosclerosis classification with a focus on genetic associations","volume":"6","author":"Bonilla","year":"2024","journal-title":"Kidney Med."},{"issue":"9","key":"B2-20260318","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000508099","article-title":"Focal segmental glomerulosclerosis: state-of-the-art and clinical perspective","volume":"144","author":"Shabaka","year":"2020","journal-title":"Nephron."},{"issue":"2","key":"B3-20260318","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/snep.2003.50025","article-title":"Trends in the epidemiology of focal segmental glomerulosclerosis","volume":"23","author":"Kitiyakara","year":"2003","journal-title":"Semin Nephrol."},{"issue":"2","key":"B4-20260318","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2215\/CJN.0000000590","article-title":"Incidence and proportion of primary focal segmental glomerulosclerosis (FSGS) among a racially and ethnically diverse adult patient population between 2010 and 2021","volume":"20","author":"Munis","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"25","key":"B5-20260318","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"D'Agati","year":"2011","journal-title":"N Engl J Med."},{"issue":"3","key":"B6-20260318","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/qjmed\/hcm142","article-title":"Primary glomerulonephritis: an update on renal survival and determinants of progression","volume":"101","author":"Moranne","year":"2008","journal-title":"QJM."},{"issue":"2","key":"B7-20260318","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.mayocp.2017.10.021","article-title":"End-stage renal disease and mortality outcomes across different glomerulonephropathies in a large diverse US population","volume":"93","author":"Sim","year":"2018","journal-title":"Mayo Clinic Proc."},{"issue":"8","key":"B8-20260318","doi-asserted-by":"crossref","first-page":"e2228701","DOI":"10.1001\/jamanetworkopen.2022.28701","article-title":"Comparing kidney health outcomes in children, adolescents, and adults with focal segmental glomerulosclerosis","volume":"5","author":"Gipson","year":"2022","journal-title":"JAMA Netw Open."},{"issue":"suppl 1","key":"B9-20260318","doi-asserted-by":"crossref","first-page":"gfab104.004","DOI":"10.1093\/ndt\/gfab104.004","article-title":"MO246 estimating delay in time to ESKD for treatment effects on proteinuria in IgA nephropathy and FSGS","volume":"36","author":"Carroll","year":"2021","journal-title":"Nephrol Dial Transplant."},{"issue":"4","key":"B10-20260318","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int."},{"issue":"8","key":"B11-20260318","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.xkme.2022.100501","article-title":"Efficacy and safety of immunosuppressive therapy in primary focal segmental glomerulosclerosis: a systematic review and meta-analysis","volume":"4","author":"Caster","year":"2022","journal-title":"Kidney Med."},{"issue":"4","key":"B12-20260318","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/ndt\/gfae025","article-title":"Management of adult patients with podocytopathies: an update from the ERA immunonephrology working group","volume":"39","author":"Mirioglu","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B13-20260318","doi-asserted-by":"crossref","first-page":"25493","DOI":"10.1038\/s41598-024-74184-z","article-title":"Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients","volume":"14","author":"Plonsky-Toder","year":"2024","journal-title":"Sci Rep."},{"issue":"2","key":"B14-20260318","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2215\/CJN.08970719","article-title":"Recurrence of FSGS after kidney transplantation in adults","volume":"15","author":"Uffing","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"5","key":"B15-20260318","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1053\/j.ajkd.2024.08.011","article-title":"Proteinuria as an endpoint in clinical trials of focal segmental glomerulosclerosis","volume":"85","author":"Mariani","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B16-20260318","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000525001","article-title":"Long-term outcomes of patients with IgA nephropathy categorized by the international IgAN risk prediction tool and by the degree of hematuria at diagnosis","volume":"146","author":"Ebbestad","year":"2022","journal-title":"Nephron."},{"issue":"1","key":"B17-20260318","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ekir.2021.11.021","article-title":"\u201cPresumed\u201d primary focal segmental glomerulosclerosis: a novel nuance for steroid therapy","volume":"7","author":"Glassock","year":"2022","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B18-20260318","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1093\/ckj\/sfaa110","article-title":"Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers","volume":"14","author":"Jacobs-Cach\u00e1","year":"2021","journal-title":"Clin Kidney J."},{"issue":"9","key":"B19-20260318","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1016\/j.mayocp.2021.01.037","article-title":"Identification of genetic causes of focal segmental glomerulosclerosis increases with proper patient selection","volume":"96","author":"Miao","year":"2021","journal-title":"Mayo Clinic Proc."},{"issue":"11","key":"B20-20260318","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"issue":"3","key":"B21-20260318","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2215\/CJN.04780517","article-title":"An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis","volume":"13","author":"Troost","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"B22-20260318","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2004070593","article-title":"Focal and segmental glomerulosclerosis: definition and relevance of a partial remission","volume":"16","author":"Troyanov","year":"2005","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B23-20260318","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B24-20260318","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000520466","article-title":"Causes of death in end-stage kidney disease: Comparison between the United States Renal Data System and a large integrated health care system","volume":"53","author":"Bhandari","year":"2022","journal-title":"Am J Nephrol."},{"issue":"20","key":"B25-20260318","doi-asserted-by":"crossref","first-page":"12607","DOI":"10.3390\/ijms232012607","article-title":"Potential urine proteomic biomarkers for focal segmental glomerulosclerosis and minimal change disease","volume":"23","author":"Chebotareva","year":"2022","journal-title":"Int J Mol Sci."},{"issue":"1","key":"B26-20260318","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12882-019-1498-4","article-title":"Focal segmental glomerulosclerosis, excluding atypical lesion, is a predictor of renal outcome in patients with membranous nephropathy: a retrospective analysis of 716 cases","volume":"20","author":"He","year":"2019","journal-title":"BMC Nephrol."},{"issue":"2","key":"B27-20260318","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis","volume":"77","author":"Troost","year":"2021","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B28-20260318","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12882-023-03405-w","article-title":"The epidemiology of primary FSGS including cluster analysis over a 20-year period","volume":"24","author":"McDonnell","year":"2023","journal-title":"BMC Nephrol."},{"issue":"1","key":"B29-20260318","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2215\/CJN.02560315","article-title":"Complete remission in the Nephrotic Syndrome Study Network","volume":"11","author":"Gipson","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B30-20260318","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1681\/ASN.2011040388","article-title":"APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy","volume":"22","author":"Kopp","year":"2011","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B31-20260318","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.arrt.2003.10.015","article-title":"Racial and ethnic differences in the incidence and progression of focal segmental glomerulosclerosis in children","volume":"11","author":"Andreoli","year":"2004","journal-title":"Adv Ren Replace Ther."},{"issue":"3","key":"B32-20260318","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1053\/j.ajkd.2022.08.010","article-title":"Racial and ethnic disparities in acute care utilization among patients with glomerular disease","volume":"81","author":"Krissberg","year":"2023","journal-title":"Am J Kidney Dis."},{"issue":"9","key":"B33-20260318","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s004670050542","article-title":"Age and ethnicity affect the risk and outcome of focal segmental glomerulosclerosis","volume":"12","author":"Sorof","year":"1998","journal-title":"Pediatr Nephrol."},{"issue":"8","key":"B35-20260318","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.34067\/KID.0000000000000499","article-title":"Minimal change disease and FSGS are a spectrum of a single disease within immune-mediated nephrotic syndrome","volume":"5","author":"Sim","year":"2024","journal-title":"Kidney360."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:11Z","timestamp":1786369211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000000898","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"2025-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}